An inhaled monoclonal antibody treatment against the SARS-CoV-2 virus may lead to self-administered therapy for COVID-19, according to preclinical tests. It was discovered at UAB and the Texas Biomedical Research Institute, and it has been licensed for development to Aridis Pharmaceuticals.
With specialized knowledge about medications and how they work to fight cancer, oncology pharmacists and pharmacy technicians play a vital role in patient care and research.
Texas Biomedical Research Institute (Texas Biomed) Professor Luis Martinez-Sobrido, Ph.D., recently released study findings, alongside colleagues at the University of Alabama at Birmingham and Aridis Pharmaceuticals, Inc. indicating that a human monoclonal antibody (hmAb) 1212C2 showed promise for further clinical development for preventative use or as a therapy for SARS-CoV-2, the virus that causes COVID-19. Earlier this year, the consortium of scientists isolated specific B cells from patients infected with SARS-CoV-2 and developed a panel of hmAbs that not only bind to SARS-CoV-2 infected cells, but also neutralize the ability of the virus to infect cells. The hmAb 1212C2 was subsequently licensed to Aridis Pharmaceuticals.
A randomized clinical trial found that drug-eluting stents (DES) with durable polymers are non-inferior to DES with biodegradable polymers in patients with acute coronary syndrome (ACS). Findings were reported today at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.
Receiving mail-order prescriptions on time is critical during the ongoing pandemic, as older adults and people with chronic conditions are avoiding leaving their homes.
There is some hope on the horizon for patients diagnosed with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. More than a dozen members of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) were authors on a study announcing the results showing promise in the fight against ALS that appeared in AANEM’s journal Muscle & Nerve.
Toxicological Sciences features leading research biotransformation, toxicokinetics, and pharmacokinetics; computational toxicology and databases; mixtures toxicology; and more in the October 2020 issue.
There are common vulnerabilities among three lethal coronaviruses, SARS-CoV-2, SARS-CoV-1 and MERS-CoV, such as frequently hijacked cellular pathways, that could lead to promising targets for broad coronavirus inhibition, according to a study by an international research team that includes scientists from the Institute for Biomedical Sciences at Georgia State University.
A research team led by Professor Hongzhe SUN, Norman & Cecilia Yip Professor in Bioinorganic Chemistry, Department of Chemistry, Faculty of Science, and Professor Kwok Yung YUEN, Henry Fok Professor in Infectious Diseases, Department of Microbiology, Li Ka Shing Faculty of Medicine of the University of Hong Kong (HKU), has discovered a novel antiviral strategy for treatment of COVID-19.
The NCCN Oncology Research Program (ORP) plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual inhibitor of the epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 2 (HER2), supported by a $2-million grant from Puma Biotechnology, Inc.
UCLA researchers have found that a drug that activates the body’s natural defenses by behaving like a virus may also make certain stealthy melanoma tumors visible to the immune system, allowing them to be better targeted by immunotherapy.
Anyone with a smartphone can download the app ViDok, which lets users pick from a library of molecules that might bind to key proteins on the SARS-CoV-2 virus, which causes COVID-19, and then can tweak the molecules to try to find a better fit.
AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center (VUMC) and optimized by AstraZeneca.
A first of its kind drug called vosoritide may increase bone growth in children with achondroplasia, the most common form of dwarfism, according to findings from a recent clinical trial published in The Lancet.
A team led by Penn Medicine has engineered powerful new antimicrobial molecules from toxic proteins found in wasp venom. The team hopes to develop the molecules into new bacteria-killing drugs, an important advancement considering increasing numbers of antibiotic-resistant bacteria which can cause illness such as sepsis and tuberculosis.
The raging lung inflammation that can contribute to death from the flu can be stopped in its tracks by a drug derived from a naturally occurring human protein, a new animal study suggests.
In a new COVID-19 clinical trial, Stuart Cohen at UC Davis Health evaluates the efficacy, safety and tolerability of monoclonal antibody combination in adults exposed to patients with COVID-19. It is the same antibody drug given to President Trump to treat his COVID-19.
A COVID-19 vaccine candidate that underwent extensive preclinical testing this spring and summer shows potent preclinical immune responses — including several that distinguish it from other COVID-19 vaccine approaches — according to a preprint deposited in the BioRxiv repository.
The Society for Obstetric Anesthesia and Perinatology (SOAP),the American Society of Anesthesiologists (ASA), the Society for Pediatric Anesthesia (SPA) the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) aim to clearly reassure pregnant women that the article “Association Between Epidural Analgesia During Labor and Risk of Autism Spectrum Disorders in Offspring,” a new retrospective database study published in JAMA Pediatrics on October 12th, 2020 does not provide credible scientific evidence that epidurals for pain relief cause autism.
Scientists at Wake Forest School of Medicine have recorded real time changes in dopamine and serotonin levels in the human brain that are involved with perception and decision-making. These same neurochemicals also are critical to movement disorders and psychiatric conditions, including substance abuse and depression.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right